Last reviewed · How we verify

NCT07329517

Comparative Effects of Resistance Training and Neuromuscular Training in Runners

Completed NA Last updated 9 January 2026
What this trial tests

NA trial testing Resistance training in Patellofemoral Pain Syndrome in 38 participants. Completed in 5 November 2025.

Timeline
21 November 2024
Primary endpoint
5 October 2025
5 November 2025

Quick facts

Lead sponsorRiphah International University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment38
Start date21 November 2024
Primary completion5 October 2025
Estimated completion5 November 2025
Sites2 locations across Pakistan

Drugs / interventions tested

Conditions studied

Sponsor

Riphah International University

Who can join

Adults 18 to 30, any sex, with Patellofemoral Pain Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This randomized controlled trial will include a sample of 38 young runners, calculated using epitool. Participants will be recruited through non-probability convenient sampling and randomly assigned to one of two groups: Group A (runner-specific resistance training) and Group B (neuromuscular training), with 19 participants in each group. The study will be conducted at the University of Lahore.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Resistance training

Trials testing the same drug.

Other recruiting trials for Patellofemoral Pain Syndrome

Currently open trials in the same condition.

Other Riphah International University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07329517.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing